<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2711543/" ref="ordinalpos=838&amp;ncbi_uid=1909179&amp;link_uid=PMC2711543" image-link="/pmc/articles/PMC2711543/figure/F5/" class="imagepopup">Figure 5. Caspase-8 tyrosine 380 may be involved in negative regulation of EGF <span class="highlight" style="background-color:">signaling</span>.  From: Critical Role for Caspase-8 in EGF <span class="highlight" style="background-color:">Signaling</span>. </a></div><br /><div class="p4l_captionBody">A) Immunoblot analysis of EGF-induced Erk and Akt pathway activation in NB7 cells lacking caspase-8 re-constituted with empty vector (E.V.), the DEDs alone (DEDs) or the “caspase domain” of caspase-8 (Casp. Dom.) (lanes 1–3, respectively). B) Immunoblot analysis of EGF-induced Erk and Akt pathway activation in NB7 cells lacking caspase-8 re-constituted with empty vector (E.V.), the catalytically inactive point mutant (C360A) or the C360A/Y380F dual mutant of caspase-8 (C360A/Y380F) (lanes 1–3, respectively). C) Immunoblot analysis of EGF-induced Erk pathway activation in NB7 cells lacking caspase-8 re-constituted with empty vector, the catalytically inactive point mutant (C360A) or the C360A/Y380F dual mutant of caspase-8 (as in Fig 5B) with or without sodium orthovanadate (200 µM) as described (lanes 1–4, respectively). D) Simplified schematic depiction of the proposed model of the critical role for caspase-8 in EGF induction of Erk pathway signaling events.</div></div>